This update clarifies that a jury, not the court, said Stratagene should pay the damages. The presiding judge must still weigh in.
 
NEW YORK (GenomeWeb News) — A jury said Stratagene should pay Invitrogen nearly $8 million in damages for infringing its patents, or around four times less than Invitrogen had hoped to win, Stratagene said today.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.